360 related articles for article (PubMed ID: 16951196)
1. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
2. Effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on IL-6, IL-8, and MCP-1 expression in human retinal pigment epithelial cell line.
Zhang XY; Hayasaka S; Chi ZL; Cui HS; Hayasaka Y
Curr Eye Res; 2005 Dec; 30(12):1105-11. PubMed ID: 16354624
[TBL] [Abstract][Full Text] [Related]
3. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38.
Arimura A; Li M; Batuman V
Ann N Y Acad Sci; 2006 Jul; 1070():1-4. PubMed ID: 16888145
[TBL] [Abstract][Full Text] [Related]
4. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases.
Li M; Maderdrut JL; Lertora JJ; Arimura A; Batuman V
Regul Pept; 2008 Jan; 145(1-3):24-32. PubMed ID: 17935800
[TBL] [Abstract][Full Text] [Related]
5. Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study.
Li M; Maderdrut JL; Lertora JJ; Batuman V
Peptides; 2007 Sep; 28(9):1891-5. PubMed ID: 17582655
[TBL] [Abstract][Full Text] [Related]
6. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
7. Altered anti-inflammatory response of mononuclear cells to neuropeptide PACAP is associated with deregulation of NF-{kappa}B in chronic pancreatitis.
Michalski CW; Selvaggi F; Bartel M; Mitkus T; Gorbachevski A; Giese T; Sebastiano PD; Giese NA; Friess H
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G50-7. PubMed ID: 17962362
[TBL] [Abstract][Full Text] [Related]
8. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
[TBL] [Abstract][Full Text] [Related]
9. The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1.
El Zein N; Badran B; Sariban E
Cell Calcium; 2008 Mar; 43(3):270-84. PubMed ID: 17651798
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury.
Li M; Balamuthusamy S; Khan AM; Maderdrut JL; Simon EE; Batuman V
Peptides; 2010 Apr; 31(4):592-602. PubMed ID: 20034524
[TBL] [Abstract][Full Text] [Related]
11. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
13. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase-activating polypeptide stimulates corticotropin-releasing factor, vasopressin and interleukin-6 gene transcription in hypothalamic 4B cells.
Kageyama K; Hanada K; Iwasaki Y; Sakihara S; Nigawara T; Kasckow J; Suda T
J Endocrinol; 2007 Nov; 195(2):199-211. PubMed ID: 17951532
[TBL] [Abstract][Full Text] [Related]
16. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus.
Mounien L; Bizet P; Boutelet I; Gourcerol G; Fournier A; Vaudry H; Jégou S
Neuroscience; 2006 Nov; 143(1):155-63. PubMed ID: 16962718
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
19. Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury.
Arimura A; Li M; Batuman V
Blood; 2006 Jan; 107(2):661-8. PubMed ID: 16204306
[TBL] [Abstract][Full Text] [Related]
20. Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus.
Costa L; Santangelo F; Li Volsi G; Ciranna L
Hippocampus; 2009 Jan; 19(1):99-109. PubMed ID: 18727050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
